Biochemical Engineering
BMS, PsiOxus add an asset to Opdivo-oncolytic virus combo deal
7th April 2021
Bristol Myers Squibb and PsiOxus Therapeutics are expanding their partnership—again. The duo first teamed up in June 2016 to study the latter’s cancer-killing virus, inking a deal later that year to combine the virus with BMS’ checkpoint inhibitor, Opdivo. Now, they’re adding a second asset from PsiOxus to the mix. Source: Fierce Biotech 7/4/2021
Back to group news